SCHEMBL564763

SCHEMBL564763

Nc1ccc(Oc2ccc(O)c(N)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.58
TDP1 Q9NUW8 3/20 0.58
CYP3A4 P08684 1/20 0.58
TSHR P16473 1/20 0.58
SMN1; SMN2 Q16637 5/20 0.57
MAPT P10636 5/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
GAA P10253 3/20 0.57
MITF O75030 1/20 0.57
GFER P55789 1/20 0.57
NLRP1 Q9C000 1/20 0.57
NOD2 Q9HC29 1/20 0.57
KDM4E B2RXH2 1/20 0.57
THRB P10828 1/20 0.57
RECQL P46063 1/20 0.57
BLM P54132 1/20 0.57
MCL1 Q07820 1/20 0.57
NR4A1 P22736 1/20 0.52
MAOA P21397 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17267881 0.94 ALDH1A1 (0.63) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL720128 0.94 ALDH1A1 (0.63) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL29464083 0.94 ALDH1A1 (0.63) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL29462465 0.91 ALDH1A1 (0.65) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL335539 0.91 ALDH1A1 (0.65) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL29935746 0.91 ALDH1A1 (0.65) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL564984 0.88 MEN1 (0.58) ALDH1A1TDP1SMN1; SMN2MAPTMEN1
SCHEMBL6853379 0.88 ALDH1A1 (0.57) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2
SCHEMBL565006 0.86 MEN1 (0.55) ALDH1A1TDP1TSHRSMN1; SMN2MAPT
SCHEMBL6274868 0.85 ALDH1A1 (0.61) ALDH1A1TDP1CYP3A4TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674029-B2 Method of preparing stabilized polymeric systems using polymeric peroxides Sunocs LLC (US) 2014-03-18 US disclosed
US-20120035307-A1 PROCESS FOR MAKING STABLIZED POLYMERIC SYSTEMS WITH NANOSTRUCTURES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-20120035315-A1 METHOD OF PREPARING STABLIZED POLYMERIC SYSTEMS USING POLYMERIC PEROXIDES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-7498467-B2 Antioxidant and bisaminophenol derivative IDEMITSU KOSAN CO., LTD. (JP) 2009-03-03 US disclosed
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-07-03 US disclosed
US-20060208227-A1 Antioxidant and bisaminophenol derivative IDEMITSU LOSAN CO., LTD (JP) 2006-09-21 US disclosed
EP-1612254-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE CBR1, CBR3, HMOX1 ALDH1A1 204/4885TDP1 1337/4885CYP3A4 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.